ClariTrial — AI Clinical Trial Intelligence

Explore/cell therapy solid tumor TIL TCR-T

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

26 results for “cell therapy solid tumor TIL TCR-T” · Phase 2 · Phase 1

Page 1 of 2

Terminated

Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma

Phase 2Clinical Stage III Cutaneous Melanoma AJCC V8Clinical Stage IV Cutaneous Melanoma AJCC V8Locally Advanced Cutaneous Melanoma

BinimetinibNivolumabQuestionnaire Administration

Jonsson Comprehensive Cancer Center3 participants1 site · United StatesCompletes Nov 2024

CT.gov Full analysis →

Recruiting

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

Phase 1Phase 2HPV-Associated Cervical CarcinomaHPV-Related CarcinomaHPV-Related Malignancy

E7 TCR-T cellsAldesleukin

Christian Hinrichs15 participants2 sites · United StatesCompletes Oct 2026

CT.gov Full analysis →

Recruiting

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

Phase 1Breast Neoplasms

Surgery for harvesting tumor-draining lymph nodesCyclophosphamideFludarabine+4 more

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University24 participants1 site · ChinaCompletes Dec 2026

CT.gov Full analysis →

Recruiting

Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

Phase 1Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8

IpilimumabPembrolizumabVaccine Therapy

Emory University18 participants4 sites · United StatesCompletes Dec 2026

CT.gov Full analysis →

Recruiting

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

Phase 1Phase 2Breast Neoplasms

Surgery for harvesting tumor-draining lymph nodesCyclophosphamideFludarabine+6 more

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University170 participants1 site · ChinaCompletes Apr 2032

CT.gov Full analysis →

Completed

Results posted

Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma

Phase 2Stage III Cutaneous Melanoma AJCC v7Stage IIIA Cutaneous Melanoma AJCC v7Stage IIIB Cutaneous Melanoma AJCC v7

AldesleukinCyclophosphamideFludarabine Phosphate+2 more

Fred Hutchinson Cancer Center11 participants1 site · United StatesCompletes Aug 2021

CT.gov Full analysis →

UNKNOWN

Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma

Phase 2Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic MelanomaPathologic Stage IIIC Cutaneous Melanoma AJCC v8

Biospecimen CollectionCyclophosphamideEchocardiography+6 more

University of Kansas Medical Center12 participants1 site · United StatesCompletes Nov 2025

CT.gov Full analysis →

By Invitation

HS-IT101 Injection in the Treatment of Advanced Melanoma

Phase 1Advanced Melanoma

HS-IT101 Injection

Qingdao Sino-Cell Biomedicine Co., Ltd.10 participants1 site · ChinaCompletes May 2026

CT.gov Full analysis →

Completed

Results posted

Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer

Phase 2Metastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8

PembrolizumabRamucirumab

Ohio State University Comprehensive Cancer Center6 participants1 site · United StatesCompletes Aug 2023

CT.gov Full analysis →

Completed

Results posted

LTX-315 and Adoptive T-cell Therapy in Advanced Soft Tissue Sarcoma (ATLAS-IT-04)

Phase 2Soft Tissue Sarcoma

LTX-315 and TILs

Lytix Biopharma AS6 participants1 site · DenmarkCompletes Jul 2021

CT.gov Full analysis →

Active

Results posted

Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1

Phase 1Phase 2Advanced Fallopian Tube CarcinomaAdvanced Malignant Solid NeoplasmAdvanced Melanoma

CyclophosphamideDecitabineLaboratory Biomarker Analysis+2 more

Roswell Park Cancer Institute15 participants1 site · United StatesCompletes Mar 2021

CT.gov Full analysis →

Not Yet Recruiting

HS-IT101 Injection for Advanced NSCLC

Phase 1Advanced Non-Small Cell Lung Cancer

CyclophosphamideFludarabineIL-2 (interleukin 2)+1 more

Qingdao Sino-Cell Biomedicine Co., Ltd.12 participants1 site · ChinaCompletes Aug 2026

CT.gov Full analysis →

Terminated

Results posted

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

Phase 1Kita-kyushu Lung Cancer Antigen 1, Human

IL-2 (Aldesleukin)CyclophosphamideKK-LC-1 TCR+12 more

National Cancer Institute (NCI)36 participants1 site · United StatesCompletes Jul 2025

CT.gov Full analysis →

Active

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Phase 2Bone SarcomaDedifferentiated ChondrosarcomaGiant Cell Tumor of Bone

AldesleukinAutologous Tumor Infiltrating Lymphocytes LN-145Autologous Tumor Infiltrating Lymphocytes LN-145-S1+6 more

M.D. Anderson Cancer Center30 participants1 site · United StatesCompletes Apr 2027

CT.gov Full analysis →

Completed

Results posted

Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma

IpilimumabNivolumab

National Cancer Institute (NCI)100 participants201 sites · United StatesCompletes Sep 2018

CT.gov Full analysis →

1–15 of 26

Explore/cell therapy solid tumor TIL TCR-T

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

26 results for “cell therapy solid tumor TIL TCR-T” · Phase 2 · Phase 1

Page 1 of 2

Terminated

Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma

Phase 2Clinical Stage III Cutaneous Melanoma AJCC V8Clinical Stage IV Cutaneous Melanoma AJCC V8Locally Advanced Cutaneous Melanoma

BinimetinibNivolumabQuestionnaire Administration

Jonsson Comprehensive Cancer Center3 participants1 site · United StatesCompletes Nov 2024

CT.gov Full analysis →

Recruiting

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

Phase 1Phase 2HPV-Associated Cervical CarcinomaHPV-Related CarcinomaHPV-Related Malignancy

E7 TCR-T cellsAldesleukin

Christian Hinrichs15 participants2 sites · United StatesCompletes Oct 2026

CT.gov Full analysis →

Recruiting

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

Phase 1Breast Neoplasms

Surgery for harvesting tumor-draining lymph nodesCyclophosphamideFludarabine+4 more

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University24 participants1 site · ChinaCompletes Dec 2026

CT.gov Full analysis →

Recruiting

Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

Phase 1Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8

IpilimumabPembrolizumabVaccine Therapy

Emory University18 participants4 sites · United StatesCompletes Dec 2026

CT.gov Full analysis →

Recruiting

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

Phase 1Phase 2Breast Neoplasms

Surgery for harvesting tumor-draining lymph nodesCyclophosphamideFludarabine+6 more

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University170 participants1 site · ChinaCompletes Apr 2032

CT.gov Full analysis →

Completed

Results posted

Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma

Phase 2Stage III Cutaneous Melanoma AJCC v7Stage IIIA Cutaneous Melanoma AJCC v7Stage IIIB Cutaneous Melanoma AJCC v7

AldesleukinCyclophosphamideFludarabine Phosphate+2 more

Fred Hutchinson Cancer Center11 participants1 site · United StatesCompletes Aug 2021

CT.gov Full analysis →

UNKNOWN

Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma

Phase 2Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic MelanomaPathologic Stage IIIC Cutaneous Melanoma AJCC v8

Biospecimen CollectionCyclophosphamideEchocardiography+6 more

University of Kansas Medical Center12 participants1 site · United StatesCompletes Nov 2025

CT.gov Full analysis →

By Invitation

HS-IT101 Injection in the Treatment of Advanced Melanoma

Phase 1Advanced Melanoma

HS-IT101 Injection

Qingdao Sino-Cell Biomedicine Co., Ltd.10 participants1 site · ChinaCompletes May 2026

CT.gov Full analysis →

Completed

Results posted

Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer

Phase 2Metastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8

PembrolizumabRamucirumab

Ohio State University Comprehensive Cancer Center6 participants1 site · United StatesCompletes Aug 2023

CT.gov Full analysis →

Completed

Results posted

LTX-315 and Adoptive T-cell Therapy in Advanced Soft Tissue Sarcoma (ATLAS-IT-04)

Phase 2Soft Tissue Sarcoma

LTX-315 and TILs

Lytix Biopharma AS6 participants1 site · DenmarkCompletes Jul 2021

CT.gov Full analysis →

Active

Results posted

Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1

Phase 1Phase 2Advanced Fallopian Tube CarcinomaAdvanced Malignant Solid NeoplasmAdvanced Melanoma

CyclophosphamideDecitabineLaboratory Biomarker Analysis+2 more

Roswell Park Cancer Institute15 participants1 site · United StatesCompletes Mar 2021

CT.gov Full analysis →

Not Yet Recruiting

HS-IT101 Injection for Advanced NSCLC

Phase 1Advanced Non-Small Cell Lung Cancer

CyclophosphamideFludarabineIL-2 (interleukin 2)+1 more

Qingdao Sino-Cell Biomedicine Co., Ltd.12 participants1 site · ChinaCompletes Aug 2026

CT.gov Full analysis →

Terminated

Results posted

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

Phase 1Kita-kyushu Lung Cancer Antigen 1, Human

IL-2 (Aldesleukin)CyclophosphamideKK-LC-1 TCR+12 more

National Cancer Institute (NCI)36 participants1 site · United StatesCompletes Jul 2025

CT.gov Full analysis →

Active

Phase 2Bone SarcomaDedifferentiated ChondrosarcomaGiant Cell Tumor of Bone

AldesleukinAutologous Tumor Infiltrating Lymphocytes LN-145Autologous Tumor Infiltrating Lymphocytes LN-145-S1+6 more

M.D. Anderson Cancer Center30 participants1 site · United StatesCompletes Apr 2027

CT.gov Full analysis →

Completed

Results posted

Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma

IpilimumabNivolumab

National Cancer Institute (NCI)100 participants201 sites · United StatesCompletes Sep 2018

CT.gov Full analysis →

1–15 of 26